Today, measurement of minimal residual disease (MRD) is one of the most reliable predictors of treatment outcomes for leukemia and lymphoma, and myeloma.
There are multiple measurement approaches for MRD testing and key criteria to consider when selecting the right tool for MRD detection.
Download this insight brief to discover what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.
Authors:
Mark Edinger, Director, Scientific Advisor, Flow Cytometry
Victor Weigman, Director, Translational Genomics
Patrick Hurban, Scientific Advisor; Senior Director and Global Head, Translational Genomics
Alan Wookey, Global Science Lead, Companion Diagnostics & Scientific Advisor, Oncology
Franklin Sederat, Director of Homatopathology
Patrice Hugo, Chief Scientific Officer
Complete the form below to access this insight brief
Related Insights
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
MASH and Liver Disease Capabilities
Labmatrix®
Tracking clinical trial samples and consents to support total sample lifecycle management
Anatomic Pathology brochure
Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services
Flow Cytometry Services
Leader in flow cytometry services for clinical trials
A Global Network to Empower Leaner Oncology Clinical Trials: Unlocking the Potential of Local Genomic Biomarker Testing in Europe
Translational Science and Innovation Laboratory (TSAIL)
Translational biomarker solutions to accelerate the adoption of assays into clinical trials though new technology evaluation and early biomarker discovery
Alzheimer’s Disease Clinical Trials
Innovative laboratory solutions to accelerate progress
Anatomic Pathology Lab Services
I-O clinical development podcast series
Pediatrics Drug Development Solutions
Download our brochure for information about our pediatric sampling capabilities
